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ABSTRACT
The endocannabinoid (eCB) system, via the cannabinoid CB1
receptor, regulates neurodevelopment by controlling neural
progenitor proliferation and neurogenesis. CB1 receptor signalling
in vivo drives corticofugal deep layer projection neuron
development through the regulation of BCL11B and SATB2
transcription factors. Here, we investigated the role of eCB
signalling in mouse pluripotent embryonic stem cell-derived
neuronal differentiation. Characterization of the eCB system
revealed increased expression of eCB-metabolizing enzymes,
eCB ligands and CB1 receptors during neuronal differentiation.
CB1 receptor knockdown inhibited neuronal differentiation of
deep layer neurons and increased upper layer neuron generation,
and this phenotype was rescued by CB1 re-expression.
Pharmacological regulation with CB1 receptor agonists or
elevation of eCB tone with a monoacylglycerol lipase inhibitor
promoted neuronal differentiation of deep layer neurons at the
expense of upper layer neurons. Patch-clamp analyses revealed
that enhancing cannabinoid signalling facilitated neuronal
differentiation and functionality. Noteworthy, incubation with CB1
receptor agonists during human iPSC-derived cerebral organoid
formation also promoted the expansion of BCL11B+ neurons.
These findings unveil a cell-autonomous role of eCB signalling that,
via the CB1 receptor, promotes mouse and human deep layer
cortical neuron development.
KEY WORDS: Cortical development, Endocannabinoids,
Neurogenesis, Projection neuron, Tetrahydrocannabinol,
2-Arachidonoylglycerol, Cerebral organoid
INTRODUCTION
Cannabinoids, the active molecules of the Cannabis plant,
and particularly the most abundant and potent of them,
Δ9-tetrahydrocannabinol (THC), exert a wide variety of
neuropsychiatric and neurological actions by impacting on the
prominent neuromodulatory role of presynaptic cannabinoid CB1
receptors (Cristino et al., 2020). Hence, deregulated expression
and function of endocannabinoid (eCB) system elements (namely,
eCB ligands, eCB receptors and eCB metabolic enzymes of
synthesis and degradation; Fig. 1A) in different neural cell
populations contribute to the complex role of this endogenous
signalling system in neurodevelopmental psychiatric disorders
(Sagredo et al., 2018), neurodegenerative diseases (Cristino et al.,
2020) and the regulation of social behaviours and emotions (Wei
et al., 2017). The neurodevelopmental function of the eCB system
is evidenced by its ability to control fundamental processes such as
neural progenitor proliferation, neuronal differentiation and
migration, axonal guidance and circuit formation (Galve-Roperh
et al., 2013; Maccarrone et al., 2014). Thus, embryonic
development is an extremely sensitive period in which exposure
to cannabinoids can induce remarkable disturbances of
endogenous cannabinoid signalling (Scheyer et al., 2019). CB1
receptors regulate long-range corticofugal neural projection
development (Mulder et al., 2008; Wu et al., 2010; Díaz-Alonso
et al., 2012). Particularly, during projection neuron differentiation,
CB1 receptor signalling controls the generation of layer V
subcerebral projection neurons (Díaz-Alonso et al., 2012; de
Salas-Quiroga et al., 2015). The eCB system also regulates the
development and morphogenesis of GABAergic interneurons
(Berghuis et al., 2005), and prenatal exposure to THC or
synthetic cannabinoid receptor agonists induces a selective
interneuronopathy with decreased hippocampal cholecystokinin-
positive basket cell generation and long-lasting alterations of
neurotransmission and behaviour (Vargish et al., 2016; de Salas-
Quiroga et al., 2020). In addition, interfering with endogenous
cannabinoid signalling, as induced by prenatal THC exposure,
leads to a subcortical hyperdopaminergic state and alterations of
noradrenergic signalling (Renard et al., 2017; Frau et al., 2019).
Overall, interfering with CB1 receptor signalling during
embryonic development exerts profound changes in neuronal
populations and network establishment. However, the cellular
mechanisms responsible for these plastic adaptations remain
largely unknown. In this sense, whereas in vivo studies have shown
a consistent role of CB1 receptor signalling in pyramidal neuron
differentiation (Díaz-Alonso et al., 2012; de Salas-Quiroga et al.,
2015), the interpretation of these observations is complex and
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makes it difficult to discriminate between cell-autonomous and
non-cell-autonomous actions (Díaz-Alonso et al., 2015). Hence, in
the present study we sought to characterize the cell-autonomous
role of the eCB system in embryonic stem cell-derived neuronal
differentiation, as well as the consequences of its pharmacological
or genetic manipulation.
Our data show that the eCB system maturates in parallel with
neuronal differentiation, regulating pyramidal neuron differentiation
via CB1 receptor signalling. Specifically, CB1 receptor knockdown
inhibits layer V neuronal differentiation. In addition, pharmacological
regulation with the monoacylglycerol lipase (MGL) inhibitor JZL-
184 and the cannabinoid receptor agonists THC and HU-210 exert an
opposite action and increase the generation of deep layer pyramidal
neurons, at the expense of upper layer pyramidal neurons, by
modulating the activity of BCL11B and SATB2 transcription factors.
These findings support a cell-autonomous role for eCB signalling and
contribute to our understanding of the neurobiological impact of
embryonic cannabinoid exposure and the associated risk of
developing neuropsychiatric alterations and neurodevelopmental
disorders.
RESULTS
The eCB system is induced during ES cell-derived default
neuronal differentiation
After neural induction, R1 mouse embryonic stem (mES) cells were
differentiated in a chemically defined medium that contained no
morphogens and in the presence of the sonic hedgehog inhibitor
cyclopamine (Gaspard et al., 2008). The expression of pluripotency,
neural stem and neural differentiation markers was monitored by
real time quantitative PCR (qPCR) and immunofluorescence to
follow ES transition to neural stem (NS) and neural differentiated
(ND) cells. Neuronal differentiation was reflected by the induction
of markers TUJ1 and NeuN, concomitant with the disappearance of
pluripotency markers and the NS marker nestin (Fig. S1A).
Transient expression of Pax6 and Tbr2 was observed during the
NS stage. Gene expression analysis of dorsal telencephalic neuronal
identity marker transcripts (Tbr1, Bcl11b, Er81, Uchl1, Cux2 and
Satb2) indicated a developmentally regulated gene expression profile
(Fig. S1B). After differentiation most cells were neurons, as indicated
by TUJ1 and NeuN expression. Immunofluorescence for vGLUT1
combined with vGAT1, or glutamate and GABA, revealed that most
Fig. 1. Gene expression analysis of eCB system
elements during mES neuronal differentiation.
(A) Scheme depicting the main elements of the eCB
system in neuronal cells, including metabolic enzymes
responsible for the regulation of 2AG and AEA levels that
may act via CB1 receptors in an autocrine or paracrine
manner depending on the cellular context.
(B-D) Expression of the eCB system genes along R1
neuronal differentiation in ES, NS and ND cells by qPCR
for enzymes producing or degrading 2AG (Daglα, Mgl,
Abhd6 and Abhd12; B) or anandamide (Napepld, Abhd4
and Faah; C) or for the CB1 receptor transcript (D). The
analyses were done on mRNA extracts from n=4-6
independent ES differentiations. (E) eCB levels of
metabolizing enzymes 2AG, AEA, OEA and PEA were
determined in the same stages as above. eCB analyses
were done on extracts from n=3 independent ES
differentiations. *P<0.05, **P<0.01, ***P<0.001
(vs ES stage). AA, arachidonic acid; ABHD,
α/β-hydrolase domain-containing protein;
AEA, N-arachidonoylethalonamine; 2AG,
2-arachidonoylglycerol; COX, cyclooxygenase; DAGL,
diacylglycerol lipase; ER, endoplasmic reticulum; FAAH,
fatty acid amide hydrolase; LOX, lipoxygenase; MGL,
monoacylglycerol lipase; NAPE-PLD, N-acyl-
phosphatidylethanolamine phospholipase D; NArPE,
N-arachidonoylphosphatidylethanolamine; N-AT,
















differentiated cells were excitatory glutamatergic neurons (79.1±
4.6% TUJ1+vGLUT1+ cells, n=4; Fig. S1C,D). ES-derived
projection neurons showed expression of laminar markers
characteristic of deep and upper layer neurons (i.e. BCL11B+ and
Satb2+ neurons, respectively) (Fig. S1E). Reaching final
differentiation, cells expressing one or the other marker did not co-
express both proteins as they are usually mutually exclusive when
fully differentiated (Greig et al., 2013). Furthermore, ES-derived
neurons were functional, as determined by patch-clamp studies
(Fig. S1F), firing action potentials in response to injected currents
from 30 pA, which is consistent with early stages of pyramidal
neurons from layer V of the mouse cerebral cortex (Zhang, 2004;
Kroon et al., 2019). The neuronal identity of patched cells was
confirmed by immunofluorescence with an anti-ER81 antibody in
biocytin-labelled cells (Fig. S1G).
To characterize the development of the eCB system during mES
neuronal differentiation, we performed qPCR gene expression
analysis of the different eCB metabolizing enzymes. Fig. 1A
illustrates the subcellular localization of the major eCB-
synthesizing and eCB-degrading enzymes, as well as the
mechanism of eCB action via CB1 receptors. The 2-
arachidonoylglycerol (2AG)-synthesizing enzyme diacylglycerol
lipase α (Daglα, recommended name Dagla) increased with neural
differentiation (Fig. 1B), whereas transcripts of the 2AG-degrading
enzyme monoacylglycerol lipase (Mgl) were equivalent in ES and
NS cells, and its levels increased thereafter with neuronal
differentiation. The expression of other 2AG-degrading enzymes,
α/β-hydrolase domain-containing proteins 6 and 12 (Abhd6 and
Abhd12), also increased at the ND stage. The Daglβ (recommended
name Daglb) isoform increased with neural differentiation, similarly
to Daglα (ES, NS and ND levels were 1.00±0.16, 4.05±0.47 and
7.41±0.26, respectively; **P=0.0068 ES vs NS; ***P=0.0008 ES
vs ND). The expression of the N-arachidonoylethalonamine
(AEA)-synthesising enzyme N-acylphosphatidylethanolamine
phospholipase D (Napepld) was low at all the stages analysed;
Abhd4 steadily increased along ES default differentiation, whereas
the AEA-degrading enzyme fatty acid amide hydrolase (Faah)
reached higher levels in ND cells (Fig. 1C). In concert with the
maturation of a functional eCB system, we observed cannabinoid
CB1 receptor upregulation. CB1 receptor transcript and protein levels
were induced during the transition from ES to multipotent NS cells
and further increased along neural differentiation (Fig. 1D). Next,
eCB levels were determined during ES neural differentiation. 2AG
levels increased steadily and reached higher values at the ND stage,
whereas the levels of the N-acylethanolamines AEA, OEA and PEA
were higher at the NS state (Fig. 1E). Immunofluorescence
characterization confirmed the presence of CB1 receptors in
pluripotent R1 cells that co-express OCT4, as well as its presence
in nestin+ NS cells and TUJ1+ neurons (Fig. 2A). At more
differentiated states, CB1 receptor expression was evident in
BCL11B+ deep layer neurons (Fig. 2B). Representative microscopy
images evidence the expression of DAGL-α, MGL, NAPE-PLD and
FAAH in ES-derived nestin+ NS cells and TUJ1+ neurons (ND), thus
confirming the maturation of the eCB system along neuronal
differentiation (Fig. 2C,D). In summary, these data demonstrate that
mES cell-derived pyramidal neuronal differentiation is accompanied
by the acquisition of a functional eCB signalling system.
CB1 receptor signalling promotes deep layer neuronal
differentiation
We assessed the impact of CB1 receptor ablation in mES-derived
neuronal differentiation by using a short-hairpin (sh) RNA
knockdown strategy. Western blot analysis showed the efficacy of
shCB1-mediated knockdown at the protein level (Fig. S2A).
Functional confirmation of CB1 receptor ablation was
demonstrated by the loss of HU-210-induced extracellular signal-
regulated kinase (ERK) activation (phosphorylation) as determined
by western blot analyses of shControl-transfected and shCB1-
transfected R1 mES-derived cells (referred to here as shCtrl-R1 and
shCB1-R1 cells, respectively) [shCtrl-R1, vehicle (1.00±0.40) vs
HU-210 (1.78±0.19), *P=0.015; shCB1-R1, vehicle (1.00±0.20) vs
HU-210 (0.98±0.07), P=0.759; n=4]. Quantification of neuronal
populations was performed in CB1 receptor knockdown ES-derived
neurons (neurons derived from shCB1-R1 cells) after
Fig. 2. Characterization of CB1 receptor expression and eCB-metabolizing
enzymes during mES cell differentiation. (A) CB1 receptor expression was
analysed by immunofluorescence in ES, NS and ND cells together with specific
markers for each stage, OCT4, nestin and TUJ1, respectively, with specific
antibodies. Representative images are shown. (B) CB1 receptor expression
immunofluorescence in deep layer neurons co-labelled with anti-BCL11B and
anti-TUJ1 antibodies. (C,D) Immunofluorescence characterization for DAGLα,
MGL and NAPE-PLD, FAAH expression in ES-derived nestin+ NS cells and
TUJ1+ neurons (at NS and ND stages). Arrows indicate BCL11B+ cells. Scale
bars: 10 µm (A,C,D); 25 µm (B).
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immunofluorescence and showed inhibited deep layer neuronal
differentiation, as evidenced by decreased BCL11B+, ER81+
neurons and increased SATB2+ upper layer neurons (Fig. 3A,B).
Gene expression analyses showed that CB1 receptor knockdown
reduced Bcl11b and Er81mRNA levels, with a concomitant increase
in the upper layer neuronal markers Satb2 and Cux2 (Fig. 3C). To
evaluate the specificity of shRNA-mediated CB1 receptor
knockdown we performed genetic rescue experiments, transfecting
shCtrl-R1 and shCB1-R1 cells with a CB1 expression plasmid that is
not recognized by the shCB1 sequence. CB1 receptor expression
rescue, as shown at the mRNA and protein level (Fig. S2B-D),
restored the ability of THC to induce ERK activation (Fig. S2E).
Importantly, CB1 receptor rescue reversed the consequences of CB1
loss of function, thus increasing BCL11B+, ER81+ neuronal
differentiation and decreasing SATB2+ cells (Fig. 3A-C). We
further proved the cell-autonomous action of CB1 receptors in deep
layer neuronal differentiation by transfecting shCB1 and shCtrl R1-
derived NS cells, with subsequent colocalization analyses of CB1
receptor and the BCL11B and SATB2 identity markers in transfected
GFP+ cells, as well as immunoreactive-area analyses for both markers
in GFP+ cells (Fig. S3A-E). Consequently, in shCB1-R1 derived
GFP+ cells, CB1 receptors and BCL11B cells were not expressed, but
SATB2 was present. In summary, these results demonstrate a cell-
autonomous role of CB1 receptor signalling in deep layer pyramidal
differentiation.
Increased eCB tone drives deep layer pyramidal neuronal
differentiation via CB1 receptors
To assess the involvement of endogenous cannabinoid tone in
ES-derived neuronal differentiation, we characterized the neuronal
populations generated under pharmacological MGL inhibition.
Treatment with JZL-184 (1 µM) during ES differentiation from 14
to 21 days in vitro (DIV), every two days, increased 2AG levels as
well as those of the other major eCB, AEA (Fig. S4A). The presence
of a high eCB tone increased neuronal differentiation towards the
generation of deep layer projection neurons, identified by the
expression of BCL11B and ER81 (Fig. 4A,B). In concert, JZL-184
treatment decreased the SATB2+ neuronal population. To determine
the role of CB1 receptors mediating JZL-184-derived eCB-driven
regulation of neurogenesis, we determined the impact of co-
incubation with the CB1 inverse agonist AM-251, which effectively
prevented JZL-184 consequences in neuronal differentiation
Fig. 3. CB1 receptors promote ES cell differentiation in deep cortical neurons. (A,B) Representative images and quantification of BCL11B+, ER81+ and
SATB2+ cells in ND cells derived from shCtrl-R1 and shCB1-R1 cells. CB1 receptor expression rescue was performed by transfection with control and
hCB1-pcDNA plasmids. (C) qPCR quantification ofBcl11b, Er81, Satb2 andCux2mRNA levels in ND cells differentiated as above. (A,B) The analyses were done
on cells from n=3 independent ES differentiations. (C) The analyses were done on mRNA extracts from n=4 independent ES differentiations. *P<0.05, **P<0.01,
***P<0.001 (vs shCtrl-R1+pcDNA); #P<0.05, ##P<0.01, ###P<0.001 (vs shCB1+pcDNA). Scale bar: 25 µm.
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(Fig. 4A,B). Moreover, in ES cells deficient in CB1 receptors
(shCB1-R1 cells), JZL-184 treatment was ineffective at inducing
BCL11B+, increasing ER81+ neurons or decreasing SATB2+ cells,
whereas these effects were evident in shCtrl-R1 cells (Fig. 4C;
Fig. S4B). This effect was also observed in shCB1- and shCtrl-
transfected R1-derived NS cells (Fig. S4C). Gene expression
analyses confirmed neuronal population immunofluorescence
studies by showing that JZL-184 increased mRNA levels of
Bcl11b and Er81 and decreased those of Satb2 and Cux2 in a CB1
receptor-dependent manner (Fig. 4D). Thus, inhibition of 2AG
degradation by JZL-184 pharmacological regulation promotes deep
layer neuronal differentiation via CB1 receptor signalling.
THC promotes deep layer neuronal differentiation via CB1
receptors
Given the evidence for the role of CB1 receptors in neuronal
differentiation in vivo (Mulder et al., 2008; Díaz-Alonso et al., 2012;
de Salas-Quiroga et al., 2015), we next characterized the impact of
CB1 receptor signalling by direct pharmacological manipulation. In
R1 cells challenged with the CB1 agonist HU-210 (100 nM), HU-
210 reduced nestin-positive NS cells and increased the number of
TUJ1+, TBR1+ cells in a CB1 receptor-dependent manner. The
effect was reversed by co-incubation with CB1 receptor antagonist
AM-251 (1 µM) (Fig. S5A-C; Table S1). In agreement, NeuN+
mature neurons increased in the presence of HU-210 (Fig. S5D;
Table S1). Quantification of TUJ1 immunofluorescence images
indicated that ES-derived neurons that differentiated in the
presence of HU-210 had an increase in the length of their main
neurite (101.8±12.8 µm in HU-210-treated vs 50.1±4.9 µm in
vehicle-treated ES-derived neurons; **P=0.0054). We then
determined the impact of THC (2 µM) on neuronal differentiation.
THC presence during ES neuronal differentiation favoured deep
layer neuronal differentiation, as indicated by increased generation
of BCL11B+ and ER81+ neurons at the expense of SATB2+ upper
layer neurons (Fig. 5A,B). THC and HU-210 pro-neurogenic action
was confirmed by gene expression analyses, and increased NeuN
mRNA levels were prevented by AM-251, hence confirming a CB1
receptor-dependent mechanism (Fig. S5E). Likewise, both
cannabinoid ligands, HU-210 and THC, increased transcript
levels of the deep layer neuronal determinants Bcl11b and Er81,
while decreasing upper layer Satb2 and Cux2 transcript levels
(Fig. S5E). As an additional analysis of the status of the BCL11B/
SATB2-regulated neuronal identity program, we examined the
expression of netrin1 axon guidance receptorsUnc5C and deleted in
colorectal cancer (Dcc), which are involved in axonal guidance of
corticofugal and callosal projection neurons, respectively (Srivatsa
Fig. 4. Monoacylglycerol lipase
inhibition by JZL-184 favours deep
layer pyramidal neuron
differentiation. (A) R1 cells were
differentiated in the presence of THC
(2 µM) in the absence or presence of
AM-251 (1 µM). Representative
immunofluorescence images are
shown after BCL11B, ER81, SATB2
and TUJ1 immunofluorescence.
(B) Quantification of BCL11B+, ER81+
and SATB2+ cells in cannabinoid-
differentiated neurons (as above)
compared with vehicle-treated cells.
(C) Quantification of BCL11B+, ER81+
and SATB2+ cells in JZL-184-treated
differentiating neurons derived from
shCtrl-R1 and shCB1-R1 cells.
(D) Gene expression analyses of
Bcl11b, Er81, Satb2 and Cux2 was
performed at ND stage by qPCR in cell
extracts as above. (B,C) The analyses
were done on cells from n=3-4
independent ES differentiations.
(D) The analyses were done on mRNA
extracts from n=3 independent ES
differentiations. *P<0.05, **P<0.01,
***P<0.001 (vs vehicle in shCtrl-R1
cells). Scale bar: 25 µm.
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et al., 2014). We found that neurons generated in the presence of
THC exhibited increased expression of Dcc transcripts and reduced
expression of Unc5C, and this was a CB1 receptor-mediated action
(Fig. 5C).
CB1 receptor regulation of Bcl11b depends on ERK and Akt
signalling
Next, we sought to investigate the intracellular signalling
mechanisms responsible for CB1 receptor regulation of Bcl11b
transcriptional activity and neuronal differentiation. Luciferase
transcriptional assays in R1 cells exposed to THC showed that CB1
receptor activation increasedMAR-A4 transcriptional activity of the
Bcl11b locus (Alcamo et al., 2008) as well as MAR1 transcriptional
activity of the Dcc locus (Fig. S6A) (Srivatsa et al., 2014). Both
effects were reversed by co-incubation with the CB1 receptor
antagonist AM-251. Likewise, JZL-184 increased transcriptional
activity of the Bcl11b and Dcc loci in a CB1 receptor-dependent
manner (Fig. S6B). Next, we performed transcriptional assays in the
HiB5 neural cell line. HiB5 cells treated with HU-210 showed
increased MAR-A4 Bcl11b transcriptional activity, and this effect
was partially counteracted by the overexpression of SATB2,
indicating appropriate regulation of the transcriptional identity
program (Alcamo et al., 2008). Moreover, HU-210-induced Bcl11b
transcriptional activity was prevented by the presence of SKI
alone and together with SATB2, whose interaction regulates
transcriptional mechanisms of callosal neuron differentiation
(Baranek et al., 2012) (Fig. S6C). Next, we assessed which CB1
receptor downstream signalling pathways (Galve-Roperh et al.,
2013) were involved in Bcl11b regulation by co-incubation with
selective inhibitors of the extracellular signal-regulated kinase
(ERK) pathway (UO126, 1 µM), Akt (Akti X, 2.5 µM), mTORC1
(rapamycin, 100 nM) and c-Jun N-terminal kinase (SP600125,
12.5 µM), as well as with a dibutyryl-cyclic AMP analogue
(2.5 µM) (Fig. S6D). CB1 receptor-induced Bcl11b-luciferase
activity was dependent on the ERK and Akt pathways, but was
independent of the mTORC1 pathway, JNK signalling and cAMP
levels. Considering previous evidence that CB1 receptor signalling
can modulate protein levels by influencing the proteasome
degradation pathway (Díaz-Alonso et al., 2017; Miller et al.,
2018), we also evaluated the impact of proteasome inhibition by the
MG-132 compound in CB1 receptor regulation of Bcl11b activation.
Treatment with MG-132 was ineffective in HU-210-induced
Bcl11b-transcriptional activity, suggesting that regulation of
proteostasis does not play a major role in CB1 receptor regulation
Fig. 5. THC favours deep layer pyramidal neuron
differentiation. (A) R1 cells were differentiated in the
presence of THC (2 µM) in the absence or presence of
AM-251 (1 µM) or vehicle. Representative
immunofluorescence images are shown after BCL11B,
ER81, SATB2 and TUJ1 immunofluorescence.
(B) Quantification of BCL11B+, ER81+ and SATB2+ cells
in cannabinoid-differentiated neurons (as above)
compared with vehicle-treated cells. (C) Gene expression
analyses of Dcc and Unc5C was performed at ND stage
by qPCR. The analyses were done in cells (A,B) and
mRNA extracts (C) from n=4-5 independent ES
differentiations. *P<0.05, ***P<0.001 (vs vehicle). Scale
bar: 25 µm.
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of Bcl11b transcriptional activity. In summary, these data
demonstrate that CB1 receptor regulation of Bcl11b-driven deep
layer pyramidal neuron differentiation is mediated by ERK and Akt
signalling, but is independent of the regulation of cAMP, mTORC1
and JNK pathways, and of proteasomal degradation.
Differentiation in the presence of THC and JZL-184 favours
neuronal maturation and activity
To further characterize the role of CB1 receptor activity during
neuronal differentiation, we determined the electrophysiological
properties of vehicle- and THC-treated neurons by patch-clamp
analyses. In current-clamp analyses, ES-derived neurons generated
in the presence of THC showed lower action potential threshold
(THC-derived neurons, −17.1±1.4 mV, n=44 cells vs vehicle-
derived neurons, −10.4±1.2 mV, n=42 cells from n=4 independent
differentiations; ***P=0.0004) and higher action potential amplitude
(THC-derived neurons, 27.6±2.6 mV, n=44 vs vehicle-differentiated
cells, 11.8±1.1 mV, n=42, ***P<0.0001) (Fig. 6A,C), getting closer
to the values of these parameters at more mature stages of layer V
pyramidal neurons (Zhang, 2004; Kroon et al., 2019). Furthermore, in
voltage-clamp recordings we found that inward currents were also
higher in THC-treated versus vehicle-treated neurons (THC-derived
neurons at −10 mM, 1223.0±106.3 pA, n=44 vs vehicle-
differentiated cells, 487.1±106.6 pA, n=42; ***P<0.0001)
(Fig. 6B,C). Similar findings were observed in JZL-184-
differentiated ES-derived neurons (Fig. 6D-F) (JZL-148 versus
vehicle for differentiated neuron action potential threshold, −21.3±
1.4 mV, n=41 cells vs −12.4±1.5 mV, n=29 cells from n=3
independent differentiations, ***P<0.0001; for action potential
amplitude, 24.1±2.1 mV, n=41 cells vs 13.3±1.2 mV, n=29 cells,
***P<0.0001; for inward current, 814.9±58.2 pA, n=41 cells vs
545.6±72.3, n=29 cells, **P=0.0047). In summary, these data
indicate that pharmacological regulation of CB1 receptor signalling
during ES-derived neuronal differentiation promotes cell functional
maturation.
CB1 receptor regulation of human iPS cell-derived organoids
increases deep layer neuronal generation
To expand the implications of our findings demonstrating the role of
CB1 receptor signalling in deep layer neuronal differentiation, we
moved to human induced pluripotent stem (hiPS) cell-derived
cerebral organoid studies. The CB1 receptor expression pattern in
human cerebral organoids recapitulated the expression pattern
observed in vivo during cortical development (Glass et al., 1997;
Díaz-Alonso et al., 2012). CB1 receptor expression was high in
differentiated microtubule associate protein 2 (MAP2)-positive
neurons. Moreover, CB1 receptor expression was evident in deep
and upper layer neurons, as identified by the expression of BCL11B
and SATB2, respectively (Fig. 7A). Cerebral organoids were
generated in the presence of the CB1 receptors agonists HU-210 and
THC (100 nM and 2 µM, respectively, from 30 to 60 DIV), and
cortical layer development was characterized by immunofluorescence.
Fig. 6. THC and JZL-184 promote the acquisition of neuronal activity and maturation. (A-E) Mouse ES-cells differentiated in the presence of THC and
JZL-148 were characterized by patch-clamp analyses. (A,D) Representative examples of the increasing currents (10 pA step) (top) injected in current-clamp
recordings and the cell responses (bottom). Black and red traces correspond to the threshold injected current and the evoked action potential firing in vehicle-
(black) and THC- or JZL-148- (red) differentiated cells, in vehicle- and THC- or JZL-148-differentiated cells. (B,E) Representative examples of series of increasing
voltages (5 mV step) (top) and the cell responses (bottom). The black trace (top) shows the injected voltage (−10mV) that evokes the highest inward current in the
cell. Black and red traces (bottom) correspond to the inward current at −10 mV in vehicle- (black) and THC- or JZL-184- (red) differentiated cells. (C,F)
Quantification of the change in the action potential threshold at −10 mM, action potential amplitude and inward current in THC- and JZL-184-differentiated
neurons compared with vehicle-differentiated neurons. The analyses were done on THC- and JZL-184-derived neurons from n=4 and 3 differentiations,
respectively. **P<0.01, ***P<0.001 (vs vehicle).
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To determine the status of CB1 receptors after differentiation in the
presence of cannabinoid agonists, CB1 immunoreactivity was
quantified. CB1 receptor levels in HU-210- and THC-differentiated
organoids did not change in comparison with vehicle-treated
organoids, suggesting the absence of CB1 receptor desensitization
(Fig. 7B). CB1 receptor activation promoted the generation of
BCL11B+ deep layer neurons and reduced that of SATB2+ upper layer
neurons (Fig. 7C,D), thus recapitulating the findings derived from
cannabinoid signalling manipulation during mouse ES cell-derived
neuronal generation (present study) and mouse embryonic
development (Díaz-Alonso et al., 2012).
DISCUSSION
In the present study we investigated the role of the eCB signalling
system in ES-derived neuronal generation. We found that the overall
expression of the different elements of the eCB system is induced
along neuronal differentiation, and the levels of the endogenous
ligands 2AG, AEA and other N-acylethanolamines are also
increased. CB1 receptor activation promoted deep layer cortical
projection neuron generation and decreased upper layer neuronal
development by regulating the transcription factors BCL11B and
SATB2, with the possible participation of other identity
determinants such as SKI. ES cell differentiation in the presence
of the CB1 receptor agonist THC or the MGL inhibitor JZL-184
promoted significant changes in electrophysiological parameters
associated with neuronal maturation, as reflected in a decrease of the
action potential threshold and an increase in the action potential
amplitude (Zhang, 2004; Kroon et al., 2019). Hence, our findings
identify a cell-autonomous role of eCB signalling, via CB1
receptors, in ES-derived differentiation of pyramidal neurons,
particularly by promoting the generation of deep layer cortical
neurons. One limitation of our study is that the relative importance
of cell-autonomous and paracrine actions of eCB signalling via CB1
receptors in pyramidal neuronal differentiation may require further
assessment using single cell transcriptomic analyses.
In the last decade, the contribution of eCB signalling to the
modulation of neuronal differentiation and morphogenesis has been
the object of intense research (Galve-Roperh et al., 2013;
Maccarrone et al., 2014). Pharmacological manipulation of CB1
receptor signalling by administration of THC (Alpár et al., 2014;
Tortoriello et al., 2014; de Salas-Quiroga et al., 2015) or the SR-
141716 antagonist (Mulder et al., 2008) has an impact on long-
range projection neuron development as well as on acquisition of
pyramidal intrinsic excitability (Bara et al., 2018). More
conclusively, conditional CB1 receptor loss of function in
glutamatergic telencephalic neurons interferes with deep layer
corticofugal and corticospinal motor neuron development (Mulder
et al., 2008; Wu et al., 2010; Díaz-Alonso et al., 2012). In retinal
neurons, CB1 receptors regulate growth cone guidance, via crosstalk
with DCC, controlling its membrane exposure in a PKA-dependent
manner (Argaw et al., 2011). eCBs also regulate oligodendrocyte-
derived Slit2, which, by acting over neuronal Robo1 receptors,
influences on corticofugal neuron development (Alpár et al., 2014).
The results herein demonstrate that the eCB system acts as a
proneurogenic signalling system that, via CB1 receptors, promotes
the differentiation and maturation of deep layer pyramidal neurons
(Díaz-Alonso et al., 2012; de Salas-Quiroga et al., 2015) by
regulating the activity of BCL11B and SATB2 transcription factors.
CB1 receptor signalling favours Bcl11b transcriptional activity by
alleviating SATB2-mediated repression via MAR sequences, and
this allows the balanced expression of netrin1-mediated growth
cone signalling receptors DCC and Unc5C (Srivatsa et al., 2014),
hence contributing to the development of subcortical projection
neurons. In addition, various N-acylethanolamine species have been
proposed to act as inhibitors of Shh signalling acting on
SMOOTHENED receptors, and independently of CB1 and other
Fig. 7. Effect of CB1 receptor activation on human iPS
cell-derived organoids. (A) Cerebral organoids were
characterized by immunofluorescence with anti-CB1 receptor
and anti-MAP2 antibodies (upper panels). Deep and upper
cortical neurons were also analysed using specific antibodies
for BCL11B and SATB2 (lower panels). (B) Organoids were
treatedwith HU-210 (100 nM), THC (2 µM) or vehicle between
30 and 60 DIV. CB1 receptor levels were quantified after
immunofluorescence. (C,D) Representative images and
quantification of BCL11B- and SATB2-neuronal generation
after immunofluorescence. Analyses were done on n=3-7
ventricles, from a minimum of 4 cerebral organoids.
***P<0.001 (vs vehicle). Scale bar: 50 µm.
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potential eCB receptors (CB2, PPARα/γ, TRPV1) (Khaliullina
et al., 2015), but the specific contribution of these mechanism to
cortical development remains unexplored.
Our observations may also have implications regarding the
impact of embryonic THC exposure and the risk of developing
neuropsychiatric alterations and neurodevelopmental disorders
(Alpár et al., 2016; Scheyer et al., 2019). Recent studies have
used hiPS-derived neuronal generation as a useful tool for
investigating the impact of THC on human development.
Transcriptomic studies on hiPS-derived neurons exposed to THC
revealed altered expression of genes involved in neurodevelopment
and synaptic function, and a pattern that associates with
neuropsychiatric conditions, particularly autism and intellectual
disability (Guennewig et al., 2018). THC-treated hiPS cell-derived
neurons showed attenuated transcriptional activity after KCl
depolarization. In addition, THC exposure during adolescence
induces developmental gene transcription changes associated with
projection neuron maturation, dendritic maturation and psychiatric
disorders (Miller et al., 2018). In a model of hiPS-derived neuronal
generation, the presence of 2AG and THC negatively regulated
neurite outgrowth, and this occurred in parallel with inhibition of the
ERK and Akt pathways (Shum et al., 2020). Similarly, a recent
report revealed that THC-treated hiPS cell-derived organoids
possess reduced neuronal activity and neurite outgrowth (Ao
et al., 2020). Hence, under these conditions, cannabinoid exposure
probably induces CB1 receptor desensitization and loss of function,
rather than its activation (Ao et al., 2020; Shum et al., 2020). In a
different neuronal lineage model, hiPS cell-derived dopaminergic
neurons generated in the presence of THC and AEAwere shown to
display dual effects, with low cannabinoid concentrations exerting a
positive effect on neuronal activity and high cannabinoid
concentrations impairing activity (Stanslowsky et al., 2016).
Considering the currently available evidence, it can be generally
concluded that CB1 receptor activity within a physiological range
(that is not accompanied by receptor desensitization) promotes
pyramidal neuron differentiation and maturation. Alternatively,
pharmacological interference of cannabinoid signalling associated
with CB1 receptor loss of function exerts detrimental consequences
on neuronal maturation. CB1 receptor regulation of BCL11B deep
layer pyramidal neuron differentiation was mediated by ERK and
Akt signalling, but was independent of cAMP, mTORC1, JNK and
proteasomal degradation. Hence, different signalling pathways are
responsible for different CB1 receptor-regulated neural cell fate
processes. For example, CB1 receptor-induced apical progenitor
transition to basal progenitor cells relies on PI3K/Akt/mTORC1
signalling (Díaz-Alonso et al., 2015), whereas BCL11B neuronal
differentiation is independent of mTORC1 activity and depends
on ERK signalling (present report). Noteworthy, CB1 receptor-
driven CSMN differentiation is a postmitotic cell-dependent
action, as demonstrated by the similar neuronal differentiation
pattern in conditional Nex-CB1 knockout mice and complete CB1
knockout mice (Díaz-Alonso et al., 2012). ERK signalling is in
turn essential in the development and acquisition of neuronal
excitability of BCL11B+ layer V neurons (Xing et al., 2016),
hence providing further support for the role of CB1 receptors in
corticospinal motor neuron development and differentiation.
Thus, eCB signalling-evoked regulation of neurogenesis relies
on a delicate balance of CB1 receptor actions by regulating cell
proliferation and basal progenitor identity, which may affect final
neuron number and direct or indirect neurogenesis (Díaz-Alonso
et al., 2015) and neuronal differentiation (Díaz-Alonso et al.,
2012; present study).
In the present study, the use of human cerebral organoids treated
with THC andHU-210 provide further support for the involvement of
CB1 receptors in stem cell-derived neuronal generation and its
modulatory role in the neuronal differentiation switch of deep layer
versus upper layer neurons. Cerebral organoids generated in the
presence of THC show alterations in progenitor proliferation (Ao
et al., 2020) and upper layer development (present study). Similarly,
in vivo THC administration alters projection neuron development and
the balance between deep and upper layer development (de Salas-
Quiroga et al., 2015; Bara et al., 2018). Importantly, alterations in the
appropriate cortical layer-selective projection neuron development is
altered in neuropsychiatric developmental diseases, including
schizophrenia, autism and intellectual disability (Willsey et al.,
2013; Ozair et al., 2018; Whitton et al., 2018). SATB2 is a genetic
risk locus for schizophrenia, mental retardation and educational
attainment (Whitton et al., 2018), and patients with mutations or
deletions within the SATB2 locus experience severe learning
difficulties and profound mental retardation (SATB2-associated
syndrome) (Zarate and Fish, 2017). Likewise, pharmacologically
induced overproduction of excitatory neurons in neocortical layer 2/3
recapitulates the development of autism-related traits (Fang et al.,
2014), and correction of upper/deep layer projection neuron
unbalance restores some of the behavioural autistic traits in a model
of human 16p11.2 microdeletion (Pucilowska et al., 2012). Hence,
the use of improved stem cell-derived neuron generation models
opens new opportunities to understand the neurodevelopmental
consequences of prenatal cannabinoid exposure (Alpár et al., 2016;
Scheyer et al., 2019), as well as to unravel the contribution of the eCB
system to neurodevelopmental diseases that result in severe
neurological alterations (i.e. refractory epilepsy) (Soltesz et al.,
2015; Cristino et al., 2020) and neuropsychiatric disorders
(Fernández-Ruiz et al., 2020).
In summary, this study demonstrates a functional role of the eCB
system in ES cell-derived neuronal generation and sheds light on the
intracellular signalling mechanisms responsible for CB1 receptor
regulation of BCL11B-mediated pyramidal neuronal differentiation.
Moreover, our findings show that, during ES neuronal differentiation,
CB1 receptor signalling promotes deep layer pyramidal neuron
development and maturation, and this proneurogenic action can be
manipulated pharmacologically, either directly by THC or other CB1
agonists, or indirectly by inhibiting MGL and increasing 2AG levels.
MATERIALS AND METHODS
Materials
All reagents, unless otherwise indicated, were from Sigma-Aldrich (St
Louis, MO). AM-251 and JZL-184 (Tocris, Bristol, UK), UO126 (Santa
Cruz, Dallas, TX), Akt inhibitor X (Calbiochem, San Diego, CA),
rapamycin (Tecoland Corporation, Irvine, CA) and THC (≥99% HPLC;
THC Pharm, Frankfurt am Main, Germany) were used. The following
materials were kindly donated: luciferase construct with MAR sequence A4
of the Bcl11b promoter (R. Grosschedl, Max-Planck-Institute of
Immunobiology and Epigenetics, Freiburg, Germany), MAR3 and
MAR2-luciferase constructs of the Dcc promoter (V. Tarabykin, Charité
Universitäts Medizin Berlin, Germany) and HU-210 (R. Mechoulam,
Hebrew University, Jerusalem, Israel).
Mouse ES cell culture and neuronal differentiation
The R1 mouse embryonic stem (mES) cell line (kindly donated by UFIEC,
ISCIII, Madrid, Spain) was employed after neural induction and
differentiation in the absence of morphogens and in the presence of
cyclopamine (Sigma-Aldrich) (Gaspard et al., 2008). R1 cells were grown
on 0.1% gelatin in ES medium containing Knockout Dulbecco’s modified
Eagle medium (DMEM) (Gibco, Carlsbad, CA) supplemented with 20%
Knockout Serum Replacement (Gibco), 1000 U/ml leukemia inhibitory
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factor (Millipore, Burlington, MA), 0.1 mM non-essential amino acids
(Lonza, Basel, Switzerland), 2 mM ultraglutamine (Lonza), 50 U/ml
penicillin and streptomycin (Lonza) and 0.1 mM 2-mercaptoethanol
(Gibco). For mES differentiation, cells were plated at low density
(5000 cells/cm2) in ES medium for 1 day. Then, the medium was changed
to Defined Default Medium (DDM) containing DMEM/F12+GlutaMAX
(Gibco) with N2 supplement (Millipore) (1×), 5 mM HEPES buffer
(Lonza), 0.1 mM non-essential amino acids (Lonza), 1 mM sodium
pyruvate (Lonza), 2.5 mg/ml AlbuMax-I (Gibco), 30 mM D-glucose
(Sigma-Aldrich), 0.1 mM 2-mercaptoethanol (Gibco) and 50 U/ml
penicillin and streptomycin (Lonza) and cells cultured for 12 days. Cells
were trypsinized, dissociated gently and filtered through 100 µm filter to
discard cell aggregates. Cells were then plated (100,000 cells/cm2) on
polylysine/laminin (Sigma-Aldrich)-coated dishes in 50% DDM and 50%
Neurobasal supplemented with B27 (Gibco) (without vitamin A, 1×), 2 mM
ultraglutamine (Lonza) and 50 U/ml penicillin and streptomycin (Lonza)
and cultured for 9 days. Cannabinoid treatment was performed during
neuronal differentiation, between days 14 and 21, and culture medium was
renewed every 2 days. Preliminary dose-dependency studies were
performed in order to determine the most appropriate ligand
concentrations for pharmacological manipulation. Lack of cell death was
determined by immunofluorescence with anti-cleaved-caspase 3 antibody
(see Fig. S7). Cell lines were routinely analysed for contamination and
mycoplasma screening.
The expression of pluripotency, neural stem and neuronal markers was
monitored by real time PCR and immunofluorescence to follow pluripotent
ES transition to the NS cell state (12 DIV) and neurons (21 DIV). CB1
receptor knockdown was performed in R1 mES cells with 10 µg pGFP-V-
RS (Origene, Rockville, MD) encoding shCtrl or shCB1 nucleofection using
Amaxa Nucleofector (AAB-1001, Lonza, program A-013, 5×106 cells).
Positive colonies were selected using puromycin (Sigma-Aldrich) and
dissociated cells were cultured as described above. In some experiments,
R1-derived NS cells were employed. Transfection was performed at
14 DIV using Lipofectamine 2000 (ThermoFisher Scientific) following the
manufacturer’s instructions. NS cells were seeded in 12-well plates,
transiently transfected with 1.5 µg shCtrl or shCB1 pGFP-V-RS (Origene)
and analysed at 21 DIV.
For CB1 receptor expression rescue, a shRNA-resistant form of human
CB1 receptor was inserted into pcDNA3.1 with an N-terminus 3×FLAG. At
14 DIV, pcDNA or pcDNA-CB1 transfection in shCtrl-R1 or shCB1-R1
cells was performed using Lipofectamine 2000 (ThermoFisher Scientific).
Cells were subsequently analysed at 21 DIV.
Immunofluorescence characterization
Immunofluorescencewas performed, after blockadewith 5% goat serum, by
overnight incubation at 4°C with the indicated primary antibodies
(Table S2), followed by incubation for 1 h at room temperature with
secondary antibodies. The appropriate anti-mouse, rat, guinea pig and rabbit
highly cross-adsorbed Alexa Fluor 488, Alexa Fluor 594 and Alexa Fluor
647 secondary antibodies (ThermoFisher Scientific, Waltham, MA) were
used. Confocal fluorescence images were acquired using LAS-X software
with a SP8 microscope, with three passes by Kalman filter and a 1024×1024
collection box. Immunofluorescence data were obtained in a blinded
manner; quantifications were obtained in 6-8 fields (250 cells/field) from the
indicated number (n) of independent experiments.
Luciferase transcriptional assays and gene expression analyses
To study BCL11B transcriptional activity, R1 and HiB5 cells (kindly
provided by Z. Kokaia, Lund University, Sweden) were seeded on 24-well
plates and transiently co-transfected with 2 µg of the luciferase reporter
vector matrix attachment region (MAR)-A4-pfosluc reporter of Bcl11b
promoter (Díaz-Alonso et al., 2012) or MAR1-pfosluc of Dcc promoter
(Vector Builder, Neu-Isenburg, Germany), using Lipofectamine 2000
(ThermoFisher Scientific) following the manufacturer’s instructions. To
correct for transfection efficacy, 200 ng Renilla luciferase (pRL-CMV) was
also co-transfected. For Bcl11b andDcc gene regulation assays, preliminary
experiments were performed with luciferase reporters of MAR-A4, MAR-
A3 and MAR3, MAR2, MAR1 sequences, respectively. MAR-A4-Bcl11b
and MAR1-Dcc were the best responders to CB1 receptor regulation and
selected for further studies. After stimulation, the luciferase activities were
quantified using the Dual-Luciferase Reporter assay system (Promega
Madison, WI) in a Lumat LB9507 luminometer (Berthold Technologies,
Bad Wildbad, Germany).
Real-time quantitative PCR
RNA was isolated using RNeasy Plus kit (Quiagen, Hilden, Germany).
cDNA was obtained with Transcriptor (Roche, Basel, Switzerland). Real-
time qPCR assays were performed using the FastStart Master Mix with Rox
(Roche) and probes were obtained from the Universal Probe Library Set
(Roche). Amplifications were run in a 7900 HT-Fast Real-Time PCR
System (Applied Biosystems, Waltham, MA). Each value was adjusted by
using 18S, TATA-box-binding protein and β-actin RNA levels as reference.
The primers used are indicated in Table S3.
Electrophysiology experiments
Control, THC- and JZL-184-derived neurons were transferred to an
immersion recording chamber and superfused at 1 ml/min with an
external solution containing (in mM) 125 NaCl, 1 MgCl2•6H2O, 3
CaCl2•2H2O, 2.5 KCl, 10 HEPES, and 20 glucose (pH 7.3, osmolality
280–290 mOsm/l) (Verma et al., 2017). Patch-clamp analyses were
performed according to standard protocols as previously described
(Martín et al., 2018). Experiments were performed at 25°C using a
temperature controller (Warner Instruments). Neurons possessing
pyramidal-shaped somas with long neurites were identified for recordings
by observation under a 40× water immersion objective and a Nomarski
condenser combined with infrared microscopy using differential interface
contrast (DIC) in an Eclipse FN1 Nikon microscope. Whole-cell
electrophysiological recordings were performed using patch pipettes
(3-5 MΩ resistance) pulled from thick-walled borosilicate glass (1.5 mm
outer and 1.1 mm inner diameter) on a P-97 puller (Sutter-Instrument) and
filled with the internal solution containing (in mM) 135 potassim gluconate,
10 KCl, 10 HEPES, 1 MgCl2, 2 ATP-Na2 (pH 7.3 adjusted with KOH;
osmolality 280–290 mOsm/l). In some experiments, 5 mM biocytin
(Tocris) was added to the internal solution for post-hoc analysis of
neuronal identity by immunofluorescence. After formation of a whole-cell
configuration (–70 mV holding potential), current- or voltage-clamp
protocols were applied. For the voltage-clamp recordings, a series of
increasing voltages (5 mV step, 50 ms duration with a 3 s interval) were
injected. For the current-clamp recordings, a series of increasing currents
(10 pA step, 100 ms duration with a 3 s interval) were injected. Recordings
were obtained by a PC-ONE amplifier, and signals were fed to a Pentium-
based PC through a DigiData1322A interface board. pCLAMP 10.2
software was used for stimulus generation, data display, acquisition, storage
and analysis.
Immunoblot assays
Protein extracts were prepared in radioimmunoprecipitation assay (RIPA)
lysis buffer supplemented with protease inhibitors. Samples were heated at
37°C for 15 min. Equal amounts of protein samples were electrophoretically
separated and transferred to PDVF membranes. After blocking with 5%
BSA, membranes were incubated overnight at 4°C with the indicated
primary antibodies (Table S2). Then, membranes were incubated with the
corresponding secondary antibodies coupled to horseradish peroxidase for
1 h at room temperature and revealed with enhanced chemiluminescence
(ECL, Biorad, Hercules, CA). The optical density of the relevant
immunoreactive bands was quantified with ImageJ software and
normalized to β-actin for the corresponding samples in the same
membranes.
Human iPS cell culture and cerebral organoid differentiation
Experiments with human induced pluripotent stem (hiPS) cells were
conducted in the Max Planck Institute of Psychiatry (Munich, Germany).
hiPS cells were maintained on Geltrex-coated dishes (ThermoFisher
Scientific) in human ES medium containing mTesR1 medium and
mTesR1 supplement (1×; Stem Cell Technologies, Vancouver, Canada).
Cells were passed after 5 min Accutase (Sigma-Aldrich) treatment. For
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cerebral organoid differentiation (Klaus et al., 2019; Buchsbaum et al.,
2020), 9000 cells/well were plated on ultralow attachment 96-well plates
(Corning, NY) in human ESmediumwith low concentration basic fibroblast
growth factor (4 ng/ml; Peprotech, Rocky Hill, NJ) and 50 µM Rho-
associated protein kinase (ROCK) inhibitor (Stem Cell Technologies).
Embryoid bodies were maintained for 6 days and then transferred to
ultralow attachment 24-well plates (Corning) in neural induction media
containing DMEM/F12+Glutamax (Gibco), N2 supplement (1:100;
Gibco), minimum essential media-nonessential amino acids (MEM-
NEAA) (1:100; Gibco) and heparin (1 µg/ml, Sigma-Aldrich) for 5 days.
On day 12, neuroepithelial tissues formed and were transferred to Matrigel
droplets (Corning) and grown in differentiation medium containing 50%
DMEM/F12+Glutamax and 50% Neurobasal containing N2 supplement
(1:200; Gibco), B27 supplement without vitamin A (1:100; Gibco), 0.1 mM
2-mercaptoethanol (Gibco), insulin (1:4000; Sigma), MEM-NEAA (1:200;
Gibco) and antibiotic-antimycotic solution (1:100; Gibco). After 4 days of
stationary growth, organoids were kept in dishes on an orbital shaker at 37°C
and 5% CO2 in differentiation medium containing B27 supplement with
vitamin A (Gibco). Organoids were analysed after cannabinoid treatment
between 30 and 60 DIV, with medium changes every 3 days. Cannabinoid
concentrations used for pharmacological regulation of organoid
development were characterized in preliminary dose-dependent studies.
The lack of toxicity was assessed by determination of organoid area,
morphology and cell death with anti-cleaved-caspase 3 antibody (see
Fig. S7). The doses of 100 nM HU-210 and 2 µM THC were finally
selected. For immunofluorescence studies in cerebral organoids, 18 μm
sections of organoids were prepared using a cryostat, and every tenth section
was collected onto a slide to obtain ten slides containing serial sections
representing the whole organoid. Immunostaining was performed as
described previously (Buchsbaum et al., 2020). For quality control and
selection of ventricles with dorsal identity to include in the analyses,
sections were stained for BCL11B and SATB2. Analysis was conducted in
12 and 10-24 different ventricles (vehicle and HU-210 or THC,
respectively) in a total of 4 and 4-7 organoids (vehicle and HU-210 or
THC, respectively). Images were acquired in sequential xyz mode with at
least 1024×1024 pixels and 0.8-1.2 μm thickness of optical z-layers. Image
analysis was conducted in Fiji; single cells were counted using the manual
cell counter plugin on a single image of the z-stack. For quantification of
neurons upon treatment, all BCL11B+ and SATB2+ cells in the
corresponding ventricle were counted and related to the total number of
DAPI+ cells inside the ventricle.
Determination of endocannabinoid levels
eCBs levels were measured in cell extracts from proliferating and
differentiated R1 cells as described (Lomazzo et al., 2015) by the
Endocannabinoids Lipidomics Group (Institute Physiological Chemistry,
University Medical Center Mainz, Mainz, Germany).
Data analyses and statistics
Results shown represent the means±s.e.m., and the number of experiments
is indicated in every case. For multiple comparisons, statistical analysis was
performed by one-way ANOVA, with a post-hoc analysis made using
Fisher’s LSD test. For analysis of two independent groups, an unpaired
Student’s t-test or Welch’s test was performed, as appropriate. Analysis was
done using GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA).
Detailed statistical analyses are provided in Table S4.
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